---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021203"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:14:19.470639+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences Q1 2023 net loss $22.2M; cash $257.7M; trials on track

## Summary
- Net loss of $22.2M ($0.31 per share) vs $16.0M ($0.26 per share) in Q1 2022.
- Cash, cash equivalents and marketable securities $257.7M as of March 31, 2023, down from $276.6M at Dec 31, 2022.
- R&D expenses increased to $18.3M from $10.9M, driven by advancing zetomipzomib and KZR-261 programs.
- PALIZADE Phase 2b trial of zetomipzomib in lupus nephritis on track to initiate in H1 2023.
- KZR-261 dose escalation study enrolling Cohort 6; dose expansion expected H2 2023 with topline data mid-2024.

## SEC filing metadata
- accession: 0000950170-23-021203
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017023021203/0000950170-23-021203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017023021203/kzr-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021203
- JSON: https://secwatch.observer/filing/0000950170-23-021203.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021203.txt

## Key facts
- Earnings Releases
  Kezar Life Sciences, Inc. reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645666/000095017023021203/0000950170-23-021203-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.